Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285: 1182–6.
Algire GH, Chalkley HW, Legallais FY, Park HD. Vascular reactions of normal and malignant tumors in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants. J Natl Cancer Inst 1945; 6: 73–85.
Gimbrone MA, Jr, Cotran R, Leapman S, Folkman J. Tumor growth and neovascularization: An experimental model using rabbit cornea. J Natl Cancer Inst 1974; 52: 413–27.
Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4–6.
Fidler IJ. Angiogenesis and cancer metastasis. Cancer J Sci Am 2000; 6 (Suppl 2): S134–41.
Fidler IJ, Rumar R, Bielenberg DR, Ellis LM. Molecular determinants of angiogenesis in cancer metastasis. Cancer J Sci Am 1998; 4: S58–66.
McNamara DAA, Harmey JH, Walsh TN et al. Significance of angiogenesis in cancer therapy. Br J Surg 1998; 85: 1044–55.
Brown LF, Berse B, Jackman RW et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Human Path 1995; 1: 86–91.
Warren RS, Yuan H, Matli MR et al. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995; 95: 1789–97.
Boocock CA, Charnock-Jones DS, Sharkey AM. Expression of vascular endothelial growth factor and its receptors FLT and KDR in ovarian carcinoma. J Natl Cancer Inst 1995; 87: 506–16.
Berkman RA, Merrill MJ, Reinhold WC et al. Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest 1993; 91: 153–9.
Connolly DT, Heuvelman DM, Nelson R et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 1989; 84: 1470–8.
Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989; 161: 851–8.
Gospodarowicz D, Abraham JA, Schilling J. Isolation and characterization of a vascular endothelial cell mitogen produced y pituitary-derived folliculo stellate cells. Proc Natl Acad Sci USA 1989; 86: 7311–5.
Keck PJ, Hauser SD, Krivi G et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989; 246: 1309–12.
Leung DW, Cachianes G, Kuang W-J et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306–9.
Conn G, Bayne ML, Soderman DD et al. Amino acid and cDNA sequences of a vascular endothelial cell mitogen that is homologous to platelet-derived growth factor. Proc Natl Acad Sci USA 1990; 87: 2628–32.
Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endo Rev 1992; 13: 18–32.
Senger DR, Vandewater L, Brown LF et al. Vascular permeability factor (VPF,VEGF) in tumor biology. Cancer Meta Rev 1993; 12: 303–24.
Dvorak HF, Sioussat TM, Brown LF et al. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors-concentration in tumor blood vessels. J Exp Med 1991; 174: 1275–8.
Klement G, Baruchel S, Rak J et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000; 105: R15–24.
Bruns CJ, Liu W, Davis DW et al. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Cancer 2000; 89: 488–99.
Tran J, Rak J, Sheehan C et al. Marked induction of the IAP family antiapoptotic proteins surviving and XIAP by VEGF in vascular endothelial cells. Biochem Biophys Res Commun 1999; 264: 781–8.
Meyer M, Clauss M, Lepple-Wienhues A et al. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J 1999; 18(2): 363–74.
Fuh G, Garcia KC, de Vos AM. The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor flt-1. J Biol Chem 2000; 275(35): 26690–5.
Ahmed A, Dunk C, Kniss D, Wilkes M. Role of VEGF receptor-1 (FLT-1) in mediating calcium-dependent nitric oxide release and limiting DNA synthesis in human trophoblast cells. Lab Invest 1997; 76(6): 779–91.
Siemeister G, Martiny-Baron G, Marme D. The pivotal role of VEGF in tumor angiogenesis: Molecular facts and therapeutic opportunities. Cancer Metastasis Rev 1998; 17: 241–8.
Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362: 841–4.
Asano K, Yukita A, Matsumoto T et al. An anti-human VEGF monoclonal antibody, MV833, that exhibits potent anti-tumor activity in vivo. Hybridoma 1998; 17: 185–90.
Borgstrom P, Bourdon MA, Hillan KJ et al. Neutralizing antivascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate 1998; 35: 1–10.
Asano M, Yukita A, Suzuki H. Wide spectrum of antitumor activity of a neutralizing monoclonal antibody to human vascular endothelial growth factor. Jpn J Cancer Res 1999; 90: 93–100.
Gerber H-P, Kowalski J, Sherman D et al. Complete inhibition of rabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res 2000; 60: 6253–8.
Soh EY, Eigelberger MS, Kim KJ et al. Neutralizing vascular endothelial growth factor activity inhibits thyrpid cancer growth in vivo. Surgery 2000; 128: 1059–65.
Sledge GW, Jr, Miller K, Novotny W et al. A phase II trial of single-agent rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) in patients within relapsed metastatic breast cancer. Proc Am Soc Clin Oncol 2000; 19: 3a.
Bergsland E, Fehrenbacher L, Meropol NJ et al. A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus 5–fluorouracil/leucovorin (FU/LV) to FU/LV alone in patients with metastic colorectal cancer. Proc Am Soc Clin Oncol 2000; 19: 939.
DeVore RF, Fehrenbacher L, Herbst RS et al. A randomized phase II trial comparing rhumab VEGF (Recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC. Proc Am Soc Clin Oncol 2000; 19: 485a (Abstr 1896).
Gordon MS, margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19: 843–50.
Brekken RA, Huang X, King S, Thorpe PE. Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res 1998; 58: 1952–9.
Brekken RA, Overholser J, Stastny VA et al. Selective inhibition of vascular endothelial growth factor (VEGF) receptor2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res 2000; 60: 5117–24.
Leppink DM, Bishop DK, Sedmak DD et al. Inducible expression of an endothelial cell antigen on murine myocardial vasculature in association with interstitial cellular infiltration. Transplantation 1989; 48(5): 874–7.
Rouan SK, Otterness IG, Cunningham AC et al. Reversal of colchicines-induced mitotic arrest in Chinese hamster cells with a colchicines-specific monoclonal antibody. Am J Pathol 1990; 137: 779–87.
Burrows FJ, Watanabe Y, Thorpe PE. A murine model for antibody-directed targeting of vascular endothelial cells in solid tumors. Cancer Res 1992; 52: 5954–62.
Ran S, Gao B, Duffy S et al. Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. Cancer Res 1998; 58(20): 4646–53.
Benjamin LE, Golijanin D, Itin A et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999; 103(2): 159–65.
Huang X, Gottstein C, Brekken RA, Thorpe PE. Expression of soluble VEGF receptor 2 and characterization of its binding by surface plasmon resonance. Biochem Biophys Res Commun 1998; 252: 643–48.
Morrow KJ, Unuvar E, King SW, Mleczko JB. Techniques for the production of monoclonal and polyclonal antibodies. In Hayat MA (ed): Colloidal Gold: Principles, Methods, and Applications. Orlando, Florida: Academic Press, 1990; 31–57.
Fidler IJ. Rationale and methods for the use of nude mice to study the biology and therapy of human cancer metastasis. Cancer Metastasis Rev 1986; 5: 29–51.
Ahlering TE, Jones PA. A new in vivo model to study invasion and metastasis of a human bladder carcinoma. Cancer Res 1987; 47: 6660–5.
Price JE, Polyzos A, Zhang RD, Daniels LM. Tumorgenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res 1990; 50: 717–21.
Zhang RD, Fidler IJ, Price JE. Relative malignant potential of human breast carcinoma cell lines established from pleural effusions and a brain metastasis. Inv Metastasis 1991; 11: 204–15.
Dunk C, Ahmed A. Vascular endothelial growth factor receptor-2–mediated mitogenesis is negatively regulated by vascular endothelial growth factor receptor-1 in tumor epithelial cells. Am J Pathol 2001; 158: 265–73.
Yoshiji H, Harris SR, Thorgeirsson U. Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. Cancer Res 1997; 57(18): 3924–8.
Shen BQ, Lee DY, Gerber H-P et al. Homologous up-regulation of KDR/Flk-1 receptor expression by vascular endothelial growth in vitro. J Biol Chem 1998; 273(45): 29979–85.
Wilting J, Birkenhager R, Eichmann A et al. VEGF121 induces proliferation of vascular endothelial cells and expression of flk-1 without affecting lymphatic vessels of chorioallantoic membrane. Dev Biol 1996; 176(1): 76–85.
Kremer C, Breier G, Risau W, Plate KH. Up-regulation of flk-1/vascular endothelial growth factor receptor 2 by its ligand in a cerebral slice culture system. Cancer Res 1997; 57(17): 3852–9.
Arbiser JL, Larsson H, Claesson-Welsh L et al. Overexpression of VEGF 121 in immortalized endothelial cells causes conversion to slowly growing angiosarcoma and high level expression of the VEGF receptors VEGF 1 and VEGFR-2 in vivo. Am J Pathol 2000; 156(4): 1469–76.
Hart IR, Fidler IJ. Role of organ selectivity in determination of metastatic patterns of B16 melanoma. Cancer Res 1981; 41: 1281–5.
Kalebic T, Garbisa S, Glaser B, Liotta LA. Basement membrane collagen: Degradation by migrating endothelial cells. Science 1983; 221:281–3.
Mori S, Ueda T, Kuratsu S et al. Suppression of pulmonary metastasis by angiogenesis inhibitor TNP-4700 in murine osteosarcoma. Int J Cancer 1995; 6: 148–52.
Fidler IJ, Gersten DM, Hart IR. The biology of cancer invasion and metastasis. Acv Cancer Res 1978; 28: 149–250.
Fidler IJ. Critical factors in the biology of human cancer metastasis: Twenty-eight G.H.A. Clowes Memorial Award Lecture. Cancer Res 1990; 50: 6130–9.
Itakura J, Ishiwati T, Shen B et al. Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer 2000; 85: 27–34.
Baek JH, Jang JE, Kang CM et al. Hypoxia-induced VEGF enhances tumor survivability via suppression of serum deprivation-induced apoptosis. Oncogene 2000; 19: 4621–31.
Gordon MS, Margolin KA, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Pharmacol 2000; 19(3): 843–850.
Barleon B, Sozzani S, Zhou D et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996; 87(8): 3336–43.
Akuzawa N, Kurabayashi M, Ohyama Y et al. Zinc finger transcription factor Egr-1 activates Flt-1 gene expression in THP-1 cells on induction for macrophage differentiation. Arterioscler Thromb Vasc Biol 2000; 20(2): 377–84.
Clauss M, Gerlach M, Gerlach H et al. Vascular permeability factor: A tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotesmonocyte migration. J Exp Med 1990; 172(6): 1535–45.